PDCD1 and head and neck squamous cell carcinoma: Currently, rejuvenating exhausted T cell by immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-PD-L1 antibodies, show promising effectiveness in solid tumors, which can be expected to improve the prognosis and overall survival in patients with R/M HNSCC.